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Abstract.	
	
The	results	of	medical-genetic	counselling	introduction	are	presented	in	
the	article	basing	on	the	results	of	the	questionnaire	survey	of	750	females	during	
general	 gynaecological	 admission	 in	 order	 to	 reveal	 the	 families	 with	 tumour	
pathology	aggregation.	The	analysis	of	clinical-genealogical	data	of	the	females	
from	 such	 families	 determined	 that	 malignant	 tumours	 association	 in	 their	
families	 corresponded	 to	 familial	 cancer	 syndrome	 (Lynch	 syndrome	 II)	 or	
hereditary	 cancer.	Basing	on	 the	 results	of	 complex	 clinical	examination	of	73	
probands	who	had	malignant	 tumours	aggregation	 in	 their	 genealogical	 trees,	
malignant	 and	 premalignant	 processes	 in	 female	 reproductive	 system	 organs	
were	detected.	The	obtained	data	 indicated	 the	effectiveness	and	reasonability	
of	 questionnaires	 as	 a	 simple	 screening	 method	 during	 gynaecological	
admission	 to	 reveal	 the	 families	 with	 tumour	 pathology	 accumulation	 and	 to	
plan	 further	 extended	 individual	 examination	 for	 females	 from	 such	 families	
aiming	 on	 timely	 detection	 and	 treatment	 of	 benign	 pathology	 of	 female	
reproductive	system	organs	and	cancer	development	prevention.		
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Problem	statement	and	analysis	of	the	recent	research		
Malignancies	 prevention	 and	 early	 diagnostics	 are	 the	 most	 important	 social-medical	
problems	in	oncology.	This	thesis	relates	entirely	to	cancer	of	female	reproductive	system	organs	
(FRSO),	the	morbidity	rate	of	which	does	not	tend	to	decrease	 in	Ukraine	according	to	the	data	of	
the	 National	 Cancer	 Register	 of	 the	 Institute	 of	 Cancer	 of	 Ukraine.	 	 In	 the	 structure	 of	 female	
oncologic	pathology	cancer	of	breast,	uterus,	and	ovaries	occupy	the	first	rank	places.		[1-4].		
Clinical	studies	demonstrate	that	despite	significant	progress	in	improving	of	methods	for	
oncologic	patients’	treatment	and	application	of	new	cytostatic	agents	their	mortality	rate	does	not	
tend	 significantly	 to	 reduce	 due	 to	 diagnostics	 of	 tumor	 processes	 at	 the	 late	 stages	 of	 their	
development.	Therefore,	from	the	position	of	anticancer	 strategies,	 the	priority	 is	 given	 	 both	 to	
prevention,	and	 to	early	diagnostics	of	precancer	and	cancer;	however	 these	problems	solving	 is	
complicated	by	the	lack	of	organized	systems	and	scientifically	based	programs.	At	the	same	time,	
one	 of	 the	 effective	 measures	 facilitating	 early	 diagnostics	 of	 precancer	 and	 cancer	 is	 the	
development	of	 screening	programs.	The	aim	of	 such	programs	 is	 to	detect	 the	disease	at	early	
stages	of	its	development,	when	the	symptoms	are	still	absent	and	curative	treatment	is	possible.	
One	can	differentiate	between	universal	and	 selective	 screenings;	 the	 latter	 is	performed	 in	 risk	
groups	 concerning	 the	 occurrence	 of	 specific	 disease	 [6-8].	 In	 our	 opinion,	 the	 achievements	 of	
clinical	oncogenetics,	where	theoretical	basics	of	genetics	and	molecular	biology	of	tumor	growth,	
and	also	practical	experience	of	oncologists	 regarding	hereditary	and	 family	cancer	 forms	of	 the	
cancer	 of	 breast,	 ovaries,	 uterus,	 colon	 and	 other	 tumors	 are	 integrated,	 may	 be	 included	 into	
selective	risk	programs	[3-5].		
The	objective	of	the	research	was	to	determine	the	role	of	clinical-genealogical	analysis	of	
genealogical	 trees	 for	determination	of	 families	with	 familial	cancer	syndrome,	and	as	a	stage	of	
genetic	screening	of	the	initial	forms	of	cancer	of	female	reproductive	system	organs.				
	
Material	 and	 methods	 of	 the	 research	 involved	 seven	 hundred	 and	 sixty	 clinical-
genealogical	 questionnaires,	 results	 of	 clinical-genealogical	 and	 clinical-morphological	
examination	of	73	females	from	families	with	familial	cancer	syndrome.				
	
Results	of	the	research		
Seven	hundred	and	sixty	 females,	who	visited	gynecologist	 for	prophylactic	examination,	
completed	 questionnaires	 for	 medical-genetic	 counseling	 by	 themselves.	 According	 to	 the	
questionnaires	 data	 in	 the	 families	 of	 73	 females	 (9.6%)	 the	 cancer	 patients	 were	 indicated	
comprising	172	persons	 in	 total.	 	Association	of	different	genesis	 tumors	 in	 families	became	 the	
reason	for	familial	cancer	syndrome	(FCS)	diagnostics.	Total	number	of	tumors	in	73	genealogical	
trees	 was	 182,	 among	 them	 there	 were	 tumors	 of	 FRSO,	 cancer	 of	 gastro-intestinal	 tract	 (GIT),	
cancer	of	respiratory	organs,	urinary	system,	prostate	and	others.	Association	of	different	genesis	
tumors	 (cancer	of	FRSO,	GIT,	 respiratory	organs	and	urinary	system,	prostate,	Hodgkin’s	disease	
and	others)	suggested	the	occurrence	of	familial	cancer	syndrome	(FCS)	in	the	families.	As	it	may	
be	 seen	 from	 the	 Table	 1,	 the	 majority	 of	 tumors	 (60/33%)	 were	 FRSO	 cancers.	 Their	 numeric	
distribution	 demonstrated	 that	 breast	 cancer	 and	 uterine	 cancer	 prevailed	 (46.7%	 and	 30.0%,	
respectively),	 ovarian	 cancer	 (OC)	was	 less	 frequent	 (20.0%),	 and	uterine	 cancer	 comprised	 only	
3.3%.			
All	 the	 females	 that	sought	counseling	underwent	complete	examination	which	 included	
gynecologist’s	examination,	ultrasound	examination	of	small	pelvis	organs	and	abdominal	cavity,	
mammary	 and	 thyroid	 glands,	 mammography,	 fibrogastroscopy,	 colonoscopy,	 blood	 and	 urine	
analyses.	This	provided	an	opportunity	to	diagnose	pathological	processes	of	benign	(49/67.1%)	and	
malignant	 (24/32.9%)	 nature	 in	 73	 (9.6%)	 of	 females	 who	 had	 relatives	 with	 cancer	 in	 their	
genealogical	trees.	Their	numeric	distribution	with	detected	pathology	of	benign	nature	depending	
Galician	Medical	Journal,	Vol.	23,	No.	1(2016)	
	
journal	homepage:	http://ojs.ifnmu.edu.ua/index.php/gmj/ 
116	
on	 clinical	 diagnosis	 and	 age	 is	 presented	 in	 Table	 1,	 according	 to	 which	 the	 most	 frequently	
detected	 pathological	 processes	 were	 the	 ones	 in	 uterine	 corpus	 (23/31.9%)	 –	 uterine	 myoma,	
adenomyosis,	atypical	hyperplasia	of	endometrium,	 less	presented	were	the	processes	 in	uterine	
cervix	 (19/26.4%)	 -	 CIN2-3,	 endocervicosis,	 and	 chronic	 endocervicitis.	 The	 rate	 of	 females	 with	
ovarian	 and	 uterine	 tubes	 pathology	 (polycystosis	 and	 ovarian	 cysts)	 and	 mammary	 gland	
(fibroadenomatosis	 and	 cysts)	was	 similar	 –14	 (by	 19.4%)	 observations	 each;	 in	 2	 females	 (2.8%)	
thyroid	gland	pathology	was	diagnosed.	
			%	
Types	of	malignant	tumors	in	the	family	trees	
Figure	1.	Numeric	distribution	of	tumors	(%)	in	760	genealogical	trees.	
Note.	 CFRSO	 –	 cancer	 of	 female	 reproductive	 system	 organs;	 CGIT	 –	 cancer	 of	 gastro-
intestinal	 tract;	CRO-	cancer	of	respiratory	organs;	CUSO	–	cancer	of	urinary	system	organs;	PC	–	
prostate	cancer.			
	
Table	1	
Numeric	distribution	of	malignant	FRSO	tumors	(%)	depending	on	their	localization	
(according	to	clinical-genealogical	data	of	60	family	trees)	
	
			
		
	
	
	
	
	 	
	
Table	2	
Numeric	distribution	of	females	with	detected	pathology	of	benign	nature	depending	on	
clinical	diagnosis	and	age	(n=49)	
Benign	processes	
	
Number	of	patients	
n	(%)	
Patients’	age	
Uterine	myoma	
CIN2-3	
Fibroadenomatosis	of	mammary	
gland	
Ovarian	polycystosis	
Uterine	adenomyosis	
Endocervicosis	
Ovarian	cyst	
14		(28.6)	
13		(26.5)	
12		(24.5)	
10		(20.4)	
8		(16.3)	
5	(10.2)	
3		(6.1)	
2		(4.1)	
23-57	
27-65	
25-43	
23-68	
28-55	
23-32	
27-50	
17,	57	
	
Localization	of	tumors	
Number	of	tumors	
n	 %	
Breast	cancer	 28	 46.7	
Uterine	corpus	cancer	 18	 30.0	
Ovarian	cancer	 12	 20.0	
Cervical	cancer	 2	 3.3	
Total	 60	 100.0	
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Mammary	gland	cyst	
Thyroid	gland	hyperplasia	
Atypical	endometrial	hyperplasia	
Hydrosalpinx	
Chronic	endocervicitis	
2		(4.1)	
1		(2.0)	
1		(2.0)	
1		(2.0)	
29,	43	
43	
49	
32	
Total	 72	/	100%	 17	–	68	(mean	
age	48±4.3	
years)	
	
Numeric	distribution	of	patients	with	detected	malignant	pathology	depending	on	clinical	
diagnosis	 and	 age	 (n=24)	 is	 presented	 in	 Table	 3,	 where	 it	 can	 be	 seen	 that	 the	 most	 frequent	
diagnosed	malignant	processes	were	those	in	FRSO	(18/75%).	In	the	genealogical	trees	according	to	
the	data	of	clinical-genealogical	analysis	33	relatives	were	detected	suffering	from	cancer	of	FRSO,	
GIT	and	other	malignant	tumors;	moreover,	after	genealogical	trees	analysis	it	was	proved	that	the	
majority	of	relatives	with	cancer	were	on	the	maternal	side	 (27/81.8%).	Due	to	timely	diagnostics	
during	probands	examination	after	medical-genetic	counseling	 in	the	majority	of	cancer	patients	
the	tumors	were	detected	at	the	stage	I	(14/58.4%).	
	
Table	3	
Numeric	distribution	of	patients	with	malignant	pathology	depending	on	clinical	diagnosis	
and	age	(n=24)	
Diagnosis		 Stage		 Age	 Cancer	 burden	 of	
genealogical	tree		
Treatment	 methods	 and	
survival	
Cervical	
cancer	
(7=29.1%)	
0-1А1,	3А	 31-39	 In	4	patients	 two	cases	
of	 uterine	 corpus	
cancer	 (UCC)	 each	 in	
the	 family	 (mothers	
and	 grandmothers	 on	
the	maternal	 side)	and	
in	 2	 patients	 1	 case	 of	
UCC	 for	 each	 in	 the	
family	 (mother)	 =	
altogether	 10	 relatives	
suffering	 from	 cancer	
in	 the	 genealogical	
trees.		
All	patients	 received	organ-
saving	 surgical	 treatment:	
cervical	 conization	 and/or	
amputation,	 follow-up	 and	
relapse-free	 period	 for	 3-6	
years.	
Breast	cancer	
(6=25.0%)	
1А-2В	 43-51	 In	4	patients	BC	was	 in	
grandmother	 on	 the	
maternal	 side,	 in	
another	 2	patients	 –	 in	
mother	 =	 altogether	 6	
relatives	suffering	from	
cancer	 in	 the	
genealogical	trees.		
Relapse-free	 follow-up	
period	 for	 3-5	 years	 after	
complex	 treatment	
completion	 (surgery	 +	
radiation	 therapy+6	 PCT	
courses	 with	 the	 scheme	
“СС”.		
Ovarian	
cancer	
(3=12.5%)	
1С	 36-51	 In	 I	 patient	 UCC	 in	
mother	 and	 OC	 in	
grandmothers	 on	 the	
maternal	 side,	 in	 2	
Relapse-free	 follow-up	
period	 for	 5-7	 years	 after	
complex	treatment	(surgical	
panhisterectomy	 and	
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patients	 mother	
suffered	 =	 altogether	 4	
relatives	suffering	from	
cancer	 in	 the	
genealogical	trees.	
omenectomy	 +	 6	 PCT	
courses	with	the	scheme		
“СС”.	
Uterine	
corpus	
cancer	
(1=4.2%)	
1	 55	 CC	 in	 father	 and	
mother	 =	 altogether	 2	
relatives	suffering	from	
cancer	 in	 the	
genealogical	trees.	
Relapse-free	 follow-up	
period	for	6	years.	
	
Uterine	
sarcoma	
(1=4.2%)	
1	 64	 Altogether	 1	 relative	
suffering	 from	 cancer	
in	the	genealogical	tree	
(CC	in	the	grandmother	
on	the	maternal	side).	
Relapse-free	 follow-up	
period	for	5	years.	
	
Thyroid	
cancer	
(1=4.2%)	
1	 47	 Altogether	 2	 relatives	
suffering	 from	 cancer	
in	 the	 genealogical	
trees	 (lung	 cancer	 in	
father	and	grandfather	
on	the	paternal	side).	
Relapse-free	 follow-up	
period	for	5	years.	
.	
	
Colon	cancer	
(4=16.7%)	
2	 54-72	 Altogether	 5	 relatives	
suffering	 from	 cancer	
in	 the	 genealogical	
trees	(2	cases	of	CC	in	1	
patient	 	=	 	mother	and	
father	 suffered	 from	
cancer,	in	3	patients	=	1	
case	 of	 gastric	 cancer	
or	CC	each,	grandfather	
and	 grandmother	 on	
the	 maternal	 side	
suffered	from	cancer).	
Relapse-free	 follow-up	
period	for	7-9	years	
	
Hodgkin’s	
disease	
(1=4.2%)	
3В	 49	 Altogether	 3	 relatives	
suffering	 from	 cancer	
in	 the	 genealogical	
trees	(leucosis	in	sister,	
father	and	grandfather	
on	 the	 paternal	 side	
suffered	 from	 lung	
cancer).	
Lived	for	7	years	
	
Total	 24	 31	–	72	
(mean	age	
57.5±2.2	
years)	
Altogether	 33	 relatives	
suffering	 from	 cancer	
in	 the	 genealogical	
trees	 (from	 them	 27	
relatives	 with	 cancer	
were	 on	 the	 maternal	
side	–	81.8%)	
All	 the	 patients	 are	 under	
observation	 –	 relapse-free	
period	is	from	3	to	9	years.	
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	 All	 the	 females	 with	 detected	 oncologic	 and	 precancer	 pathology	 received	 treatment	
according	to	the	standards	established	in	Ukraine.	These	females	together	with	their	relatives	were	
assigned	 to	 the	groups	of	potential	genetic	risk	of	oncologic	pathology	development,	considering	
the	 possibility	 of	 primary-multiple	 malignant	 tumors	 development	 in	 the	 families	 with	 FCS.	 In	
addition,	the	individual	plan	of	dispensary	observation	was	made	for	each	female	with	fixed	dates	
of	repeated	visits	and	examinations.			
	 Hense,	from	the	list	of	benign	processes	the	significant	number	of	pathological	processes,	
which	may	cause	hormonal	homeostasis	disorders	is	noteworthy.	 	These	disorders	have	complex	
pathogenesis,	as	the	disorder	of	cyclic	processes	of	hypothalamo-hypophysial-ovarian	systems	 is	
known	 to	 lead	 to	alteration	of	 sexual	hormones	 reception	and,	 in	 general,	 to	hormonal	balance	
alterations	 [1-5].	 	Such	changes	 in	hormonal	 reception	are	 the	cause	of	ovulatory	and	menstrual	
functions	 deteriorations	 that	 promote	 the	 development	 of	 such	 conditions	 as	 endometriosis,	
uterine	 myoma,	 hyperplastic	 processes	 in	 endometrium,	 ovarian	 cysts	 and	 polycystosis,	 and	
mammary	gland	fibroadenomatosis.	 	Fundamental	studies	demonstrated	two	major	mechanisms	
of	hormone	action:	promotor	 (physiological),	 that	 is	hormone	action	 is	directed	at	 cells	division	
stimulation,	and	genotoxic,	when	the	hormones	or	their	derivatives	affect	DNA	structure	inducing	
mutations	that	cause	genome	instability,	and	may	facilitate	tumor	grown	initiation	and	promotion	
[2,	 6-8].	 From	 the	 standpoint	 of	 the	 presented	 above	 information,	 the	 significance	 of	 hormonal	
homeostasis	disorder,	morphological	equivalents	of	which	are	changes	 in	 the	described	patients	
with	FCS	in	their	families,	has	extremely	important	clinical	significance.	This	is	a	reasonable	basis	
to	 include	 such	 patients	 into	 genetic	 risk	 groups	 of	 cancer	 development	 because	 it	 was	
demonstrated	 that	 in	FCS	cases	germinal	mutations	 in	 the	genes	 –	suppressors	of	tumor	growth	
BRCA1	and	BRCA2	 [3-5]	are	seen.	The	 transfer	of	 these	mutations	 from	generation	 to	generation	
according	to	laws	of	heredity	and	presence	of	hormonal	homeostasis	disorders	are	the	risk	factors	
of	tumor	development	in	such	situations.	All	this	is	a	valuable	proof	of	the	fact	that	the	knowledge	
of	family	and	individual	cancer	history	and	testing	of	mutations	in	the	genes	–	suppressors	should	
become	supplementary	criteria	in	the	strategy	of	genetic	prophylaxis	and	screening	of	FRSO	cancer.	
The	 obtained	 results	 demonstrate	 the	 reasonability	 of	 application	 and	 introduction	 of	 medical-
genetic	counseling	of	 females	 from	 the	 families	with	 tumor	pathology	aggregation.	The	obtained	
results	 may	 form	 a	 basis	 for	 establishment	 of	 the	 register	 for	 families	 with	 familial	 cancer	
syndrome	and	hereditary	cancer	in	female	population	of	Cherkassy	region.	
	
Conclusions	
1. Among	the	genealogical	trees	of	760	females	73	(9.6%)	families	were	detected	having	
tumor	aggregation	by	FCS	type.	At	clinical-genealogical	analysis	of	genealogical	trees	with	
FCS	were	determined	in	67.1	%	of	females	with	benign	processes	and	in	32.9%	of	women	
with	malignant	processes	of	different	genesis.	FRSO	cancer	rate	was	82.2%.		In	14	(58.4%)	
of	24	patients	the	malignant	process	was	diagnosed	at	stage	I.	
2. Clinical	 and	 genealogical	 analysis	 of	 the	 families	 and	 the	 knowledge	 of	 family	 and	
individual	 cancer	 history	 is	 an	 effective	 approach	 to	 reveal	 the	 families	 with	 FCS,	 and	
complex	 clinical-morphological	 examination	 of	 such	 persons	 allows	 detecting	 benign	
processes,	including	precancer	processes	and	tumor	processes	at	initial	stages.	
3. Knowledge	 of	 family	 and	 individual	 cancer	 history,	 along	 with	 testing	 of	 mutations	 of	
genes-suppressors	 of	 tumor	 growth	 BRCA1	 and	 BRCA2,	 allows	 detecting	 genetically	
determined	forms	of	FRSO	cancer,	which	is	a	basis	for	organization	of	genetic	screening	in	
the	system	of	preventive	measures	and	diagnostics	of	early	forms	of	tumor	processes.	
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